Categories AlphaGraphs, Earnings, Health Care
Key highlights from Biogen’s (BIIB) Q4 2022 earnings results
Biogen Inc. (NASDAQ: BIIB) reported fourth quarter 2022 earnings results today.
Total revenue fell 7% year-over-year to $2.54 billion.
Net income attributable to Biogen Inc. was $550.4 million, or $3.79 per share, compared to $368.2 million, or $2.50 per share, last year. Adjusted EPS rose 19% to $4.05.
Both the top and bottom line numbers beat expectations.
For the full year of 2023, adjusted EPS is expected to range between $15.00-16.00.
Prior performance
Looking for more insights on the earnings results? Click here to access the full transcripts of the latest earnings conference calls!
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on
